In a report released on January 20, Matthew Hedberg from RBC Capital maintained a Buy rating on PTC (PTC – Research Report), with a price target of $230.00. The company’s shares closed ...
Shares of PTC Inc. PTC inched 0.24% higher to $187.58 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.09% to 5,930.85 ...
Looking forward, PTC Therapeutics has provided a broad revenue guidance range for 2025, indicating potential volatility in expected performance. Additionally, the company’s anticipated R&D and ...
PTC (Nasdaq: PTC), a global software company that enables manufacturers and product companies to digitally transform how they engineer, manufacture, and service the physical products that the ...
More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...
Neil Barua, who took the wheel of Seaport-based PTC Inc. (Nasdaq: PTC) last February, earned $16.4 million in total compensation in 2024, according to the company's federal securities filings ...
But on the bright side, you can make far more than 100% on a really good stock. One great example is PTC Inc. (NASDAQ:PTC) which saw its share price drive 145% higher over five years. The last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback